Human ANGPTL4 protein (Recombinant-Active) (N-His) (STJP012247)
SPECIFICATIONS
HostMammalian Cells
ConjugationUnconjugated
ImmunogenHomo sapiens (Human)
General Information
| Short Description | Recombinant-Active-Human ANGPTL4-N-His protein was developed from mammalian cells and has a target region of N-His. For use in research applications. |
| Applications | ELISA/WB |
| Host | Mammalian Cells |
| Note | STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Product Properties
| Conjugation | Unconjugated |
| Dilution Range | Reconstitute in sterile water for a stock solution. |
| Formulation | Lyophilized from a solution in PBS pH 7.4, 5% Trehalose, 5% Mannitol. |
| Storage Instruction | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for one week. Store at-20 to-80°C for twelve months from the date of receipt. |
| Endotoxin | <0.1 EU/Mu g of the protein by the LAL method. |
| Immunoreactivity | Immobilised human ANGPTL4 at 1 Mu g/mL, 100 Mu L/well, can bind the human LILRB2 with an ED50 of 70-350 ng/mL. |
Target Information
| Gene Symbol | ANGPTL4 |
| Gene ID | 51129 |
| Uniprot ID | ANGL4_HUMAN |
| Immunogen | Homo sapiens (Human) |
| Immunogen Region | Pro166-Ser406 |
Additional Info
| Post Translational Modifications | N-glycosylated. ANGPTL4 N-terminal chain: Forms disulfide-linked dimers and tetramers. Cleaved into a smaller N-terminal chain and a larger chain that contains the fibrinogen C-terminal domain.both cleaved and uncleaved forms are detected in the extracellular space. The cleaved form is not present within the cell. |
| Function | Mediates inactivation of the lipoprotein lipase LPL, and thereby plays a role in the regulation of triglyceride clearance from the blood serum and in lipid metabolism. May also play a role in regulating glucose homeostasis and insulin sensitivity (Probable). Inhibits proliferation, migration, and tubule formation of endothelial cells and reduces vascular leakage. Upon heterologous expression, inhibits the adhesion of endothelial cell to the extracellular matrix (ECM), and inhibits the reorganization of the actin cytoskeleton, formation of actin stress fibers and focal adhesions in endothelial cells that have adhered to ANGPTL4-containing ECM (in vitro). Depending on context, may modulate tumor-related angiogenesis. ANGPTL4 N-terminal chain: Mediates inactivation of the lipoprotein lipase LPL, and thereby plays an important role in the regulation of triglyceride clearance from the blood serum and in lipid metabolism. Has higher activity in LPL inactivation than the uncleaved protein. |
| Protein Name | Angiopoietin-Related Protein 4Angiopoietin-Like Protein 4Hepatic Fibrinogen/Angiopoietin-Related ProteinHfarp Cleaved Into - Angptl4 N-Terminal Chain - Angptl4 C-Terminal Chain |
| Database Links | Reactome: R-HSA-1989781Reactome: R-HSA-381340Reactome: R-HSA-8963889Reactome: R-HSA-9762292Reactome: R-HSA-9841922 |
| Cellular Localisation | SecretedExtracellular SpaceExtracellular MatrixThe Unprocessed Form Interacts With The Extracellular MatrixThis May Constitute A Dynamic ReservoirA Regulatory Mechanism Of The Bioavailability Of Angptl4 (Probable) |
| Alternative Protein Names | Angiopoietin-Related Protein 4 proteinAngiopoietin-Like Protein 4 proteinHepatic Fibrinogen/Angiopoietin-Related Protein proteinHfarp Cleaved Into - Angptl4 N-Terminal Chain - Angptl4 C-Terminal Chain proteinANGPTL4 proteinARP4 proteinHFARP proteinPGAR proteinPP1158 proteinPSEC0166 proteinUNQ171 proteinPRO197 protein |
Information sourced from Uniprot.org